Exploring the future: Opportunities and challenges in cell and gene therapy for rare diseases

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies. With many of these conditions lacking approved treatments, the standard care often revolves around symptom management or substitution therapies. Even when treatments are available, they are frequently costly and deliver only modest improvements.

For pharma companies, advancing new treatments is no easy task. The small population sizes and limited natural history data make clinical trial development particularly difficult, often resulting in smaller evidence bases.

Cell and gene therapy presents a potential solution to these challenges, offering the possibility to treat diseases at a cellular or genetic level. However, as promising as these therapies are, they come with their own unique set of hurdles. Misconceptions about their effectiveness and concerns about their complexity can add additional layers of uncertainty – particularly in the rare disease space, where conditions are already poorly understood.